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Abstract
Soon after the first novel influenza A (H1N1) death was documented in Korea on August 15, 2009, prompt treatment with
antiviral drugs was recommended when an infection was suspected. Free antiviral drugs were distributed to patients who
met the case definition in the treatment guidelines, and patients prescribed the antiviral drugs were included in the
Antiviral Drug Surveillance System (ADSS). A total of 2,825,821 patients were reported to the ADSS from September 1 to
December 31, 2009. Odds ratios were calculated to compare the risks of severe diseases, as indicated by general hospital
admissions or intensive care unit (ICU) admissions according to demographic characteristics, underlying medical conditions,
and behavioral factors. Approximately 6% of the total population received antiviral drugs during the study period. Of these,
2,709,611 (95.9%) were outpatients, 114,840 (4.06%) were hospitalized, and 1,370 (0.05%) were admitted to the ICU.
Children aged 0–9 yr accounted for 33.94% of all reported cases, whereas only 3.89% of the patients were $ 60 yr. The
estimated incidence of novel influenza A (H1N1) during the pandemic was 5.68/100 of all reported cases. Mortality due to
influenza A (H1N1) during the pandemic was 0.33/100,000, with the highest mortality of 1.31/100,000 for patients aged $
60 years. Severe pandemic H1N1 influenza was associated with the presence of one or more underlying medical conditions
in elderly aged $ 60 years and with lower economic status. Moreover, influenza A (H1N1) appeared to be age-specific in
terms of mortality. Although the incidence and admission rates of influenza A (H1N1) were higher in younger age groups,
fatal cases were much more likely to occur in the elderly ($60 years). In contrast to earlier influenza A (H1N1) reports, the
risks of a severe outcome were elevated among those who were underweight (body mass index , 18.5 kg/m2).
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Introduction
The first confirmed case of novel influenza A (H1N1) in Korea
was registered on May 1, 2009 [1], and 225 deaths had been
reported by January 1, 2010 [2]. Soon after the first death was
documented on August 15, 2009, the Korean Health Authority
revised the national guidelines so that confirmed tests would no
longer be required, and general and prompt treatment with
antiviral drugs was recommended as soon as the infection was
suspected. The reformed guidelines were published on September
1, 2009 [3].
The Ministry of Health and Welfare in Korea stopped reporting
the number of confirmed cases on September 22, 2009, because
these data clearly did not represent a true picture of the pandemic
[4]. Even the World Health Organization (WHO) stopped
reporting confirmed cases after July 6, 2009 [5]. Every country
has a different healthcare system and a different overall
socioeconomic status, which made accessibility and lab capability
of the testing data unequal. Accuracy of test results depends on the
timing of the samples taken, and some tests are not entirely reliable
[6]. Moreover, testing is not necessary in most cases.
Korea operated the Antiviral Drug Surveillance System (ADSS)
nationally to monitor the use of antiviral drugs such as oseltamivir
or zanamivir. All hospitals and pharmacies administering or
dispensing these drugs were instructed to enter information
pertaining to the prescriptions into the ADSS, a web-based
system. In this report, we describe the epidemiological character-
istics of all nationally representative patients in the ADSS from
September 1 to December 31, 2009. This is the first study in
Korea using nationwide surveillance. We also investigated social




The ADSS began to be used on September 21, 2009. The
Korean Health Authority distributed antiviral drugs beginning
on August 21, 2009, and the use of antiviral drugs prior to the
ADSS was also entered by each medical institute. Patients who
met the case definition in the treatment guidelines were supplied
free antiviral drugs from national storage repositories through
455 hospitals and nearly 500 local pharmacies operating as
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clinical bases [3] at the beginning of this program. All local
pharmacies were supplied with the antiviral drugs after October
30, 2009 [1].
The antiviral treatment guidelines for suspected cases were
defined as influenza-like illness (temperature $ 37.8uC, with at
least one of the following symptoms: rhinorrhea, nasal congestion,
sore throat, or cough) and one of following subgroups [7]: 1. high-
risk groups such as young children # 59 months, women who
were pregnant or 2 weeks postpartum, elderly $ 65 years and
people with chronic illnesses (pulmonary disease, cardiovascular
disease, diabetes, kidney disease, liver disease, malignancy,
immune suppression, and others such as cognitive disorders,
spinal damage, and neuromuscular disorders), 2. medical person-
nel previously in contact with a patient with confirmed or
suspected infection, 3. admitted patients, and 4. cases diagnosed as
necessary based on a doctor’s decision.
According to the Korean Influenza Surveillance Scheme,
influenza-like illnesses exceeded the 2009 baseline (2.6/1000) [8]
at the pandemic level during week 34 (August 16–22), sharply
increased beginning on week 42 (October 11–17), and peaked
during week 45 (November 1–7) at 44.96/1,000 outpatients [9].
Similarly, the number of antiviral prescriptions peaked during
weeks 44–46 (October 25–November 15) (Fig. 1).
Information from the ADSS consisted of gender, age, region,
date of prescription, and dispensing pattern: outpatient, inpatient,
or intensive care unit (ICU). We classified patients who had a lab-
confirmed recoding on the national health insurance claim during
the study period as a confirmed case. Novel influenza A (H1N1)
infection was confirmed in Korea by real-time reverse transcrip-
tion polymerase chain reaction (RT-PCR) analysis or by
conventional RT-PCR at the Research Institute of Public Health
and Environment in each province or at a medical center capable
of laboratory testing [10].
We assessed economic status according to the type of
beneficiary, either covered by National Health Insurance (NHI)
or by the Medical Aid program, a Korean public assistance
program. In 2008, 96.3% of the total population was covered by
the NHI; the remaining individuals (3.7%) were indigent or in
lower income brackets and were covered by the Medical Aid
program [11].
Various ‘‘underlying diseases’’ were identified from the diag-
nosed health benefit claim codes for patients from September 1,
2008 to August 31, 2009, 1 year prior to the study period. The
underlying conditions were classified into pulmonary disease,
cardiovascular disease, diabetes, kidney disease, liver disease,
malignancy, immune suppression, and others such as cognitive
disorders, spinal damage, and neuromuscular disorders as
mentioned in the antiviral treatment guidelines.
We assumed a case to be a death associated with novel influenza
A (H1N1) when a patient with a lab-confirmed record during the
study period lost beneficiary eligibility due to death as of
December 31, 2009. Data of body mass index (BMI) and smoking
and drinking habits for adults aged $ 20 yr, who were part of the
study population, were collected from the 2008 and 2009 Periodic
Health Examination Program (PHEP) records. PHEP is a free-of-
charge service benefit for NHI beneficiaries who are householders,
employees, or dependents of these two groups aged $ 40 yr. The
National Health Insurance Cooperation (NHIC) suggests that
every recipient under the category receive the service at least
biannually, and 66% of those recipients received medical
examinations in 2009 [12].
Patient confidentiality was maintained through the use of
unidentified data forms from the NHIC, where all national health
benefits are managed and where ADSS was operated during the
pandemic. The initial data source was part of the routinely
collected information by NHIC for administrative purposes, and
the ADSS dataset was reconstructed without personal identifica-
tion revealed to monitor demand for the antiviral drugs. The
Institutional Review Board (IRB) of the School of Public Health,
Seoul National University waived the need for written informed
consent from the participants, because no patient identification
information was included in the dataset. This decision was based
on the ‘‘protection of study participants’’ regulation of the IRB of
the School of Public Health, Seoul National University.
Figure 1. Number of antiviral drug users in the Antiviral Drug Surveillance System (ADSS) from September to December 2009. The
frequency dropped at the time of clinic and pharmacy closings on Sundays.
doi:10.1371/journal.pone.0047634.g001
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Statistical Analysis
We used descriptive analyses of cases by gender, age, health
benefit, region, and the presence or absence of an underlying
disease. Means (6 standard deviation) and medians of continuous
variables and percentages of categorical variables were generated.
Multiple logistic regressions were used to identify independent risk
factors of disease severity, and the results are expressed as odds
ratios (ORs) and 95% confidence intervals (CIs). The disease
severities we considered in this study were the proportion of severe
outcomes such as general admissions or admissions to the ICU.
Complementary analyses were carried on confirmed cases out to
examine results consistency. We included variables of the month
and day of the week to correct for changes in the sensitivity and
specificity of clinical surveillance schemes throughout the epidemic
and for accessibility to clinics according to when they were open.
All statistical analyses were performed with SAS 9.1 (SAS Institute,
Cary, NC, USA) and Microsoft Excel (Redmond, WA, USA).
Table 1. Characteristics of patients registered in the Antiviral Drug Surveillance System in Korea (September-December 2009).
Characteristics Total case (%) N = 2825821 Confirmed case (%) N = 665231
Female sex 1413423 (50.02) 350458 (52.66)
Age, yr (Mean, Median) (19.9 6 17.3, 14) (16 6 13, 13)
0–4 415854 (14.72) 77277 (11.62)
5–9 543088 (19.22) 160049 (24.06)
10–19 870002 (30.79) 263048 (39.54)
20–29 305766 (10.82) 68740 (10.33)
30–39 281657 (9.97) 44647 (6.71)
40–49 185747 (6.57) 26368 (3.96)
50–59 113698( 4.02) 15608 (2.35)
60+ 110009 (3.89) 9494 (1.43)
Health benefit, Insurance 2737755 (96.88) 645191 (96.99)
Region, Province* 1560224 (55.22) 345593 (51.96)
Seoul{ 547441 (19.37) 131895 (19.83)
Pusan{ 181792 (6.43) 52205 (7.85)
Taegu{ 129533 (4.58) 27636 (4.15)
Inchon{ 156035 (5.52) 37862 (5.69)
Kwangju{ 95661 (3.39) 22861 (3.44)
Taejon{ 87245 (3.09) 24375 93.66)
Ulsan{ 67454 (2.39) 22731 (3.42)
Kyonggi* 716922 (25.37) 157670 (23.70)
Gangwon* 84992 (3.01) 30476 (4.58)
Chungbuk* 97465 (3.45) 21886 (3.29)
Chungnam* 114198 (4.04) 24065 (3.62)
Chonbuk* 105107 (3.72) 22107 (3.32)
Chonnam* 90440 (3.20) 17759 (2.67)
Kongbuk* 129076 (4.57) 25711 (3.86)
Kongnam* 201173 (7.12) 42541 (6.39)
Jeju* 20851 (0.74) 3378 (0.51)
$ 1 underlying disease n = 759165 (26.9) n = 160377 (24.1)
Lung disease 529398 (59.24) 120248 (66.66)
Cardiovascular disease 63610 (7.12) 9240 (5.12)
Diabetes mellitus 61529 (6.89) 7396 (4.10)
Kidney disease 23420 (2.62) 4620 (2.56)
Liver disease 103358 (11.57) 18348 (10.17)
Malignancy 25885 (2.9) 3576 (1.98)
Immune suppression 50057 (5.6) 9978 (5.53)
others 36322 (4.06) 6978 (3.87)
NOTE. {Seven large cities in Korea.
*Nine provinces in Korea.
doi:10.1371/journal.pone.0047634.t001
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Results
Epidemiological Characteristics
In total, 2,825,821 antiviral drug users were registered in the
ADSS from September 1 to December 31, 2009, including
665,231 confirmed cases (Table 1). More than 50% of the patients
were reported in and around the Korean capital area. A total of
716,922 patients were from Kyonggi Province, 547,441 were from
Seoul, and 156,035 were from Incheon. Females accounted for
50.02% of all patients and 52.66% of confirmed cases. The mean
age was 19.9 yr (617.3 yr) and the median age was 14 yr (range,
0–102 yr). Substantially more cases were recorded in the younger
group than those in the older group. Children aged 0–9 yr
accounted for 33.94% of all cases, whereas only 3.89% of the
patients were $ 60 yr. The school-age group of 10–19 yr had the
highest number of confirmed cases. A total of 759,165 (26.9%)
patients had one or more underlying medical comorbidities, and
59.24% of these had lung disease including asthma, and 65.12% of
the patients with lung disease were # 9 yr. Liver disease was
equally distributed over all age groups. The incidences of diabetes
and malignancy increased with age. The distribution of the types
of disease for confirmed cases was similar to the distribution for all
cases.
Most of the cases in Korea from September to December 2009
were community infections [13]. The estimated incidence of novel
influenza A (H1N1) during the pandemic was 5.68/100 for all
cases, and 1.34/100 were confirmed cases. Infection occurred
mostly in the younger age groups (Fig. 2A), and the 5–9 yr age
group being the most affected (20.42/ 100), whereas the ICU
admission rates were similar for patients in the 0–9 yr group and
in the group $ 60 yr (Table 2). We counted a case as a death
when the patient was confirmed as having the infection but was
dead at the end of the study period. The mortality due to influenza
A (H1N1) using this criterion was 0.33/100,000, with the highest
mortality of 1.31/100,000 for patients $ 60 yr. The estimated
incidence, admission rate, and ICU rate in the confirmed group
were highest in the younger groups and decreased gradually in the
older groups (Fig. 2B).
The number of patients exposed to novel influenza A (H1N1)
was highest in and around the capital area, but the incidence per
100 people was high in Gwangju (6.67) and Chungbuk (6.38). The
highest incidence rate of severe outcomes was in Gangwon
(4.89 ICU admissions/100,000), where most of the districts are
rural areas. After classifying the region by city and province, the
incidence of influenza A (H1N1) was higher in provinces where
the proportions of 0–19 yr patients (24.30%) and those $ 60 yr
(15.99% ) were greater than those in the city (22.73% and 13.57%
respectively).
Factors Associated with Severe Outcomes
Of the total antiviral drug users in the ADSS, 2,709,611 (95.9%)
were outpatients, 114,840 (4.06%) were inpatients, and 1,370
(0.05%) were admitted to ICUs. Females comprised 49.86% of the
outpatients, 53.57% of the inpatients, and 61.17% of the ICU
Figure 2. Epidemic curves of confirmed or suspected influenza A (H1N1) (A) and confirmed only (B). Proportion of severe outcomes
among confirmed or suspected influenza A (H1N1) cases by age group (C) and confirmed cases only (D).
doi:10.1371/journal.pone.0047634.g002
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patients. ORs increased with disease severity in the multivariate
analyses (Table 3). The average age of the outpatients was 19.8 yr
(616.9 yr) and the median was 14 yr (range, 0–102 yr). The mean
and median ages increased to 51.6 (628.5 yr) and 62 yr (range, 0–
96 yr), respectively, for those in the ICU. Compared to those aged
30–39 yr, those $ 60 yr were significantly more likely to have a
severe outcome (ICU; OR, 30.988; 95% CI, 22.594–42.501). The
proportion of NHI beneficiaries was 96.68% for outpatients, but
this value decreased to 94.77% and 89.12% for general and ICU
admissions, respectively. NHI beneficiaries were less likely to
experience severe illness than patients in the Medical Aid program
(ICU; OR, 0.460; 95% CI, 0.387–0.548). Underlying disease was
associated with an increased risk of severe outcome. The OR was
1.280 (95% CI, 1.263–1.297) for inpatients and 2.065 (95% CI,
1.829–2.332) for those admitted to the ICU.
Confirmation rates differed by age group in a subset of lab-
confirmed cases. The majority (75.22%) of confirmed patients was
, 20 yr, and the confirmation rates were high in school-aged
individuals, with the highest at 30.24/100 cases for those aged 10–
19 yr. Only 3.89% of confirmed cases were elderly ($60 yr), and
their confirmation rate was the lowest at 8.63/100 cases. Analyses
restricted to lab-confirmed cases showed similar results, with the
ORs of those $ 60 yr higher than those of the younger groups, but
the magnitude of the ORs was reduced compared with ORs in all
cases (Table 4).
Likelihood of Death
Although the incidence and admission rate for influenza A
(H1N1) were higher in younger individuals, the proportions of
inpatients and those admitted to the ICU among antiviral drug
users were higher in the elderly ($ 60 yr) (Fig. 2C, 2D) and the
mortality rate for those $ 60 yr was noticeably higher than that in
other groups. The death rate significantly differed by the time the
prescription was filled with 0.01/100 for outpatients and 0.23 and
5.23/100 for admission and ICU, respectively. Because the stage
that the drugs were used influenced mortality, we adjusted the
ORs for death including the variable for the time of filling the
prescription. Compared to those aged 30–39 yr, those $ 60 yr

















0–4 2263425 18.37 13.08 4.64 3.41 3.27 1.86 0.22
5–9 2659544 20.42 7.82 5 6.02 4.18 3.91 0.11
10–19 6811650 12.77 3.38 1.2 3.86 1.73 0.63 0.13
20–29 7028262 4.35 1.35 0.64 0.98 0.49 0.18 0.11
30–39 8371533 3.36 0.91 0.51 0.53 0.27 0.16 0.08
40–49 8729495 2.13 0.63 1.03 0.3 0.17 0.11 0.22
50–59 6508077 1.75 0.89 2.14 0.24 0.22 0.29 0.25
60+ 7401159 1.49 1.76 9.9 0.13 0.21 0.62 1.31
total 49773145 5.68 2.31 2.75 1.34 0.81 0.58 0.33
Region
City 22984378 5.5 2.23 2.28 1.39 0.88 0.53 0.28
Seoul 10208302 5.36 2.49 3.07 1.29 0.96 0.8 0.18
Pusan 3543030 5.13 2.65 1.41 1.47 1.14 0.25 0.51
Taegu 2489781 5.2 1.21 0.72 1.11 0.42 0.16 0.32
Inchon 2710579 5.76 1.75 2.36 1.4 0.67 0.3 0.26
Kwangju 1433640 6.67 1.07 1.46 1.59 0.36 0.28 0.07
Taejon 1484180 5.88 3.4 2.96 1.64 1.15 0.34 0.4
Ulsan 1114866 6.05 1.87 1.26 2.04 1.06 0.36 0.54
Province 23788767 5.82 2.37 3.15 1.29 0.76 0.69 0.37
Kyonggi 11460610 6.26 2.52 3.16 1.38 0.82 0.56 0.28
Gangwon 1512870 5.62 2.05 4.89 2.01 0.72 1.12 0.93
Chungbuk 1527478 6.38 2.05 3.54 1.43 0.63 0.39 0.46
Chungnam 2037582 5.6 1.71 2.7 1.18 0.48 0.29 0.49
Chonbuk 1854508 5.67 1.35 1.35 1.19 0.57 0.16 0.16
Chonnam 1913004 4.73 1.96 1.73 0.93 0.6 0.21 0.63
Kongbuk 2669876 4.83 2.3 3.48 0.96 0.67 0.3 0.37
Kongnam 3250176 6.19 3.46 4.25 1.31 1.05 2.03 0.37
Jeju 562663 3.71 2.35 1.6 0.6 0.85 0 0
NOTE. Incidence = no. of each cases 4 population of each age group.
{All patients registered in the Antiviral Drug Surveillance System (ADSS) were confirmed or suspected to have the infection.
doi:10.1371/journal.pone.0047634.t002
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were significantly more likely to die (OR, 20.747; 95% CI,
9.2874–46.348). Meanwhile, the risks of the younger group were
much lower (0–4 yr; OR 0.317; 95% CI, 0.099–1.010; 5–9 yr,
OR. 0.106; 95% CI, 0.027–0.411).
Behavioral Variables
Registered patients $ 20 yr old in the biannual PHEP data
numbered 397,390 among the total study population. Of those,
14,876 patients were hospitalized, and 258 were admitted to the
ICU (Table 5). Approximately 71% were aged 20–49 yr but
84.50% of ICU patients were $ 50 yr. The proportion of
individuals with underlying diseases in the BMI subgroup was
higher than that in the total group. Underweight (BMI , 18.5 kg/
m2) patients had a higher risk of severe illness. Although the
number of high BMI patients was greater than the number of low
BMI patients for all outcomes, the proportion of obese patients
(BMI . 25.0 kg/m2) decreased, whereas the proportion of low
BMI patients increased as the infection became more severe
(Table 5). The adjusted ORs for underweight patients were
significantly different from the ORs of patients whose weight was
normal. For all patients $ 20 yr, the ORs were 1.436 (95% CI,
1.334–1.546) for inpatients and 2.953 (95% CI, 1.830–4.767) for
those admitted to the ICU (Table 6). Although the cases in
variable categories with behavior variables among confirmed cases
were not sufficient for a precise analysis, the trends in the ORs
remained the same in confirmed cases. The ORs for low BMI
patients were 1.189 (95% CI, 1.024–1.379) for inpatients and
2.387 (95% CI, 0.827–6.894) for those admitted to the ICU or
who died. All ORs were adjusted with other variables such as
gender, age, region, and underlying condition.
Discussion
During the study period from September–December 2009,
5.69% of the Korean population was prescribed antiviral drugs
and 2.3/1,000 people were admitted as confirmed or suspected
cases of infection. The proportion of females was higher among
severe infection cases. A dominant prevalence of female cases was
also reported in Canada [14]. However, a gender-specific infection
could not be concluded clearly, because other variables associated
with females, such as pregnancy, [15,16] were not included in the
present analyses.
Kim et al. (2010) [17] studied the trend of the spread of this
novel influenza strain by comparing three monitoring tools used in
Korea during the pandemic. The patterns of spread from the three
methods were generally similar but details, such as peak time, were
different. We found that illness severity was greater among patients
who were $ 60 yr, who were in a low-income group, and who had
comorbidities. This finding persisted in the results for analysis of
the confirmed group only.
Most previous studies have reported the characteristics of novel
influenza A (H1N1) lab-confirmed cases. However, as novel
influenza A (H1N1) became a pandemic, routine testing for the
infection was not recommended, and prompt treatment was given
instead to mitigate damage from the infection. Therefore, an
analysis of only confirmed cases would certainly lead to selection
bias in the results. Because the entire population that was given
antiviral drugs, including those that were treated during the peak





n = 114840 OR (95% CI)
ICU No.
(%) n = 1370 OR (95% CI)
Female sex 1351062 (49.86) 61523 (53.57) 1.165 (1.151–1.179) 838(61.17) 1.996 (1.786–2.231)
Age (yrs)(Mean, Median) (19.8616.9, 14) (22623.4, 13) (51.6628.5, 62)
0–4 386140(14.25) 29,609(25.78) 2.519 (2.453–2.587) 105(7.66) 1.283 (0.896–1.838)
5–9 522150(19.27) 20805(18.12) 1.359 (1.322–1.336) 133(9.71) 1.443 (1.020–2.040)
10–19 846901(31.26) 23019(20.04) 0.931 (0.907–0.957) 82(5.99) 0.641 (0.442–0.930)
20–29 296259(10.93) 9462(8.24) 1.152 (1.117–1.188) 45(3.28) 0.985 (0.649–1.497)
30–39 273967(10.11) 7647(6.66) reference 43(3.14) reference
40–49 180175(6.65) 5482(4.77) 1.030 (0.994–1.067) 90(6.57) 3.016 (2.096–4.339)
50–59 107784(3.98) 5775(5.03) 1.648 (1.590–1.708) 139(10.15) 6.580 (4.660–9.290)
60+ 96235(3.55) 13041(11.36) 3.575 (3.463–3.692) 733(53.50) 30.988 (22.594–42.501)
Health benefit, Insurance 2627703(96.68) 108831(94.77) 0.585 (0.569–0.602) 1221(89.12) 0.46 (0.387–0.548)
Region, Province 1495874(55.21) 63507(55.33) 0.977 (0.965–0.989) 843(61.67) 1.311 (1.175–1.463)
$1 underlying disease{ n = 713383(26.33) n = 44887(39.09) 1.28 (1.263–1.297) n = 895(65.33) 2.065 (1.829–2.332)
Lung disease 498284(59.87) 30670(51.36) 1.169 (1.152–1.186) 444(28.59) 1.493 (1.326–1.682)
Cardiovascular disease 57398(6.90) 5929(9.93) 1.286 (1.247–1.327) 283(18.22) 1.531 (1.325–1.768)
Diabetes mellitus 55435(6.66) 5804(9.72) 1.256 (1.216–1.297) 290(18.67) 1.401 (1.214–1.617)
Kidney disease 20996(2.52) 2342(3.92) 1.801 (1.720–1.885) 82(5.28) 2.049 (1.619–2.584)
Liver disease 97918(11.76) 5322(8.91) 1.037 (1.006–1.068) 118(7.60) 0.740 (0.609–0.899)
Malignancy 22232(2.67) 3489(5.84) 2.298 (2.208–2.391) 164(10.56) 2.526 (2.123–3.006)
Immune suppression 46515(5.59) 3438(5.76) 1.344 (1.295–1.395) 104(6.70) 1.909 (1.549–2.352)
others 33533(4.03) 2721(4.56) 1.436 (1.378–1.496) 68(4.38) 1.502 (1.171–1.927)
NOTE. Odds ratios (ORs) were adjusted with eight categories of underlying disease.
{Results for multivariate logistic regression without considering the various underlying diseases.
doi:10.1371/journal.pone.0047634.t003
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period of the pandemic, were considered in this study, we were
able to conclude that there was no difference between the results
for all cases and the results for only confirmed cases. This increases
the confidence of our findings.
The age-specific immunity of novel influenza A (H1N1)
reported in a previous study by Miller et al. (2010) [18] suggested
that a great portion of older people had pre-existing immunity to
the novel influenza A (H1N1) virus as a result of pre-exposure to
antigenically related influenza A earlier in their lifetime. More-
over, the significantly higher incidence of infection in those #
19 yr occurred presumably because these patients were exposed to
an increased potential for transmission within their schools, and
confirmation tests were performed vigorously [19]. In our study,
the characteristics of novel influenza A (H1N1) appeared to be
age-specific in terms of mortality. Younger aged individuals were
susceptible to the influenza A (H1N1) infection and had a higher
incidence of severe outcomes than those in other age groups. But,
the persons in the elderly group ($60 yr) were much more likely to
suffer a severe case or even more fatal cases once they became
infected. Schools in Korea were not closed nationwide during the
novel influenza A (H1N1) outbreak, and the decision was left to
the discretion of each school.
The incidence and admission rate in the younger age group of
outpatients and inpatients were higher than those in the older
group. ICU incidence was high in the groups , 10 and $ 60 yr.
Considering that the prevalence was significantly lower in the
older group, the risk of severity was assumed to be higher in those
aged $ 60 yr. This result is consistent with our supplementary
analysis of confirmed cases. The incidences in children, who were
confirmed patients classified as outpatients, inpatients, and those
admitted to the ICU, were higher than those in the older group,
but an exception was found for deaths assumed to be caused by
novel influenza A (H1N1), which were higher in the older group
than those in children. The mortality rate showed a J-shaped curve
with the greatest risk in those aged $ 60 yr (1.31/100,000). This
finding can be interpreted as most young children recovered from
the severe illness, whereas severe illness more often led to death in
the older group.
A risk factor associated with obesity was not found in Korea,
which differed from results reported in Mexico [20] and the
United States [21]. However, being underweight was one of the
risk factors for severity in our study. The reason for the reverse
association between BMI and severe outcome is unclear. We used
the general cut-off point of BMI as recommended by the WHO.
However, Asian populations have different associations between
BMI, the percentage of body fat, and health risks compared to
Western populations [22]. Blumentals et al. [23] identified the
highest influenza pneumonia rates in underweight individuals in
their retrospective cohort study of UK patients and suggested an
association between low BMI, malnutrition, and immune function.
This was also most likely influenced by the observation that a
substantial proportion of patients with a severe underlying disease
such as cardiovascular disease or chronic pulmonary disease have
a lean body mass in general [24]. One of the limitations of this
study was that information regarding the severity of the individual
underlying diseases did not exist.
We showed various outcomes in the incidence and mortality
among regions. Regional variations in illness magnitude may have





n = 40,539 OR 95% CI
ICU No.(%)
n = 290 OR 95% CI
Female sex 327892 (52.51) 22225 (54.82) 1.116 (1.093–1.139) 196 (64.05) 1.670 (1.257–2.220)
Age (yrs) (16613, 13) (17617, 11) (24626, 9)
0–4 69833 (11.18) 7402 (18.26) 1.781 (1.694–1.873) 42 (13.73) 1.800 (0.820–3.952)
5–9 148813 (23.83) 11132 (27.46) 1.318 (1.257–1.382) 104 (33.99 2.348 (1.120–4.921)
10–19 251228 (40.24) 11777 (29.05) 0.841 (0.802–0.881) 43 (14.05) 0.743 (0.339–1.627)
20–29 65265 (10.45) 3460 (8.53) 1.002 (0.949–1.059) 15 (4.90) 0.694 (0.260–1.851)
30–39 42379 (6.79) 2254 (5.56) reference 14 (4.58) reference
40–49 24901 (3.99) 1454 (3.59) 1.032 (0.964–1.105) 13 (4.25) 1.110 (0.384–3.210)
50–59 14162 (2.27) 1427 (3.52) 1.626 (1.515–1.746) 19 (6.21) 3.308 (1.346–8.133)
60+ 7805 (1.25) 1633 (4.03) 2.929 (2.719–3.156) 56 (18.30) 10.129 (4.380–23.423)
Health benefit, Insurance 606123 (97.08) 38782 (95.67) 0.659 (0.626–0.694) 286 (93.46) 0.687 (0.370–1.278)
Region, Province 325043 (52.06) 20365 (50.24) 0.921 (0.902–0.940) 185 (60.46) 1.520 (1.148–2.011)
$1 underlying disease{ 146481 (23.46) 13,737 (33.89) 1.328 (1.298–1.359) 159 (51.96) 2.029 (1.516–2.717)
Lung disease 109708 (67.02) 10422 (63.29) 1.287 (1.255–1.319) 118 (49.79) 2.069 (1.541–2.779)
Cardio. disease 8080 (4.94) 1,132 (6.87) 1.312 (1.224–1.407) 28 (11.81) 1.887 (1.083–3.288)
Diabetes 6413 (3.92) 950 (5.77) 1.286 (1.189–1.391) 33 (13.92) 2.273 (1.286–4.017)
Kidney disease 4123 (2.51) 491 (2.98) 1.461 (1.326–1.611) 6 (2.53) 1.282 (0.466–3.529)
Liver disease 17012 (10.39) 1319 (8.01) 1.043 (0.982–1.107) 17 (7.17) 1.057 (0.557–2.005)
Malignancy 3047 (1.86) 518 (3.15) 1.764 (1.596–1.950) 11 (4.64) 2.441 (1.177–5.061)
Immune supp. 9062 (5.54) 901 (5.47) 1.279 (1.191–1.375) 15 (6.33) 2.137 (1.130–4.044)
others 6234 (3.81) 735 (4.46) 1.463 (1.351–1.584) 9 (3.78) 1.558 (0.682–3.558)
NOTE. Odd ratios (ORs) were adjusted with eight categories of underlying disease.
{Results for multivariate logistic regression without considering the various underlying diseases.
doi:10.1371/journal.pone.0047634.t004
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been caused by the density and composition of the population.
Approximately 49% of the Korean population lives in the capital
area (Seoul) and around this area, including the city of Incheon
and Kyonggi province from among the 16 cities and provinces in
Korea. One social issue in Korea is that the average age of the
population in rural areas is increasing; thus, it is assumed that age-
specific immunity and mortality were the cause of the observed
variations in incidence in the regions, together with differences in
the transmission potential according to population density. After
classifying the region into two groups such as city and province,
the incidence of influenza A (H1N1) and the risk of severe
outcomes were higher in provinces. The proportion of working
people aged in their 20 s to 50 s among residents, the lower risk
groups for influenza A (H1N1), was greater in the city.
We found that individual economic status influenced infection
severity. Although only two groups were used in this study,
consistent results were found throughout the analysis. Patients in
the Medical Aid program showed greater disease severity.
Accessibility to medical treatment and hygiene could differ
according to individual economic conditions. This may have
caused a delay in seeking medical care after symptom onset. The
length of time from symptom onset to treatment is associated with
illness severity [25].
Underlying medical conditions are a risk factor for severe
influenza [26]. Echevarria-Zuno et al. (2009) [20] reported that the
presence of an underlying disease increased the risk of dying to by
6.1 fold in Mexico. We found that the OR for death cases with
underlying disease was 2.218 (95% CI, 1.504–3.271) adjusted by
all other variables including the phase of prescription refill.
Our study is an aggregated case report including almost all cases
of confirmed and suspected infection during and around the
pandemic peak. Individual case reports at an early stage of a
pandemic are important to make appropriate policy decisions.
However, while such reports at the early stage of a pandemic can
explain groups susceptible to transmission; they cannot help
identify risk groups in the total population. Moreover, these data
cannot predict the degree of severity, because the aim of
hospitalization at this time is isolation in general [27]. Including
the probable cases of novel influenza A (H1N1) in this study would
not likely result in overestimating the incidence rate considering
that novel influenza A (H1N1) is a relatively mild infection [28] or
even an asymptomatic infection for which a majority of cases were
not captured [29].
Our study had several limitations. Given that we used data from
the ADSS, there was an absence of detailed clinical symptom
information. Data related to the type of medication may be limited
in its ability to reflect the true conditions of the infection. Another
limitation was that prescription information was entered by staff at
hundreds of clinics across the county, which may have reduced
reliability of the data, but antiviral drugs distributed from national
Table 5. Baseline characteristics of the body mass index (BMI) subset.









(n = 3,830) ICU (n = 24)
Sex, female 187,023 (48.93) 7,449 (50.07) 180 (69.77) 32,442 (51.45) 2123 (55.43) 10 (41.67)
Age (yrs)
20–29 83,978 (21.97) 2,521 (16.95) 8 (3.10) 19,454 (30.85) 911 (23.79) 3 (12.50)
30–39 109,830 (28.73) 3,129 (21.03) 11 (4.26) 19,263 (30.55) 923 (24.10) 4 (16.67)
40–49 79,851 (20.89) 2,138 (14.37) 21 (8.14) 11,722 (18.59) 632 (16.50) 1 (4.17)
50–59 63,447 (16.60) 2,739 (18.41) 38( 14.73) 8,784 (13.93) 738 (19.27) 5 (20.83)
60+ 45,150 (11.81) 4,349 (29.24) 180 (69.77) 3,835 (6.08) 626 (16.34) 11 (45.83)
BMI(kg/m2) 23.4863.43 23.2963.49
Underweight (BMI,18.5) 20,613 (5.39) 1,029 (6.92) 25 (9.69) 3,889 (6.17) 251 (6.55) 1 (4.17)
Normal (18.5#BMI,25.0) 245,678 (64.27) 9,448 (63.51) 160 (62.02) 41,276 (65.46) 2,430 (63.45) 15 (62.50)
Obese (25.0#BMI) 115,965 (30.34) 4,399 (29.57) 73 (28.29) 17,893 (28.38) 1,149 (30.00) 8 (33.33)
Smoking{ 90,171 (25.26) 3,176 (23.22) 57 (25.56) 15,461 (26.03) 805 (22.52) 7 (33.33)
Drinking{ 63,152 (18.71) 2,121 (16.27) 31 (14.49) 10,762 (19.19) 547 (16.02) 2 (10.00)
Region, province 203,347 (53.20) 8,268 (55.59) 169 (65.50) 32,091 (50.89) 1,857 (48.49) 15 (62.50)
underlying disease 113,344 (29.65) 6,633 (44.59) 189 (73.26) 15,726 (24.94) 1,403 (36.63) 13 (54.17)
Lung disease 42081 2806 88 5812 609 9
Cardiovascular disease 21248 1594 69 2548 297 5
Diabetes mellitus 23755 1781 63 2653 327 6
Kidney disease 4744 445 10 679 6 1
Liver disease 34396 1643 34 5051 368 2
Malignancy 8011 973 56 1058 142 2
Immune suppression 10782 682 9 1606 170 2
others 7850 472 10 1048 98 0
NOTE. {current smoker.
{drink more than once or twice per week.
doi:10.1371/journal.pone.0047634.t005
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stores were counted and rechecked by the district health center to
verify their use and the number of remaining drugs. We were also
unable to gather information on underlying disease severity, which
precluded a conclusion as to which type of underlying disease most
influenced outcomes.
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